Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2014
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 07 Jun 2017 Biomarkers information updated
- 07 Mar 2013 Planned End Date changed from 1 Jun 2014 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.